Impaired FADD/BID signaling mediates cross-resistance to immunotherapy in Multiple Myeloma.

Commun Biol · 2023 · PMC10739907 · PMID 38129580

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Nevertheless, in our Daratumumab resistant RRMM patients a clear trend towards low expression of FADD/BID was visible.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.